Mizuho Securities analyst Difei Yang maintained a Hold rating on Audentes Therapeutics (NASDAQ: BOLD) today and set a price target of $38. The company’s shares closed on Friday at $38.24, close to its 52-week high of $42.61.
Yang commented:
“We came away very encouraged by the data which showed continued improvements in the first cohort of patients, as well as early positive data in the expansion cohort. We see a stronger probability of success for the AT-132 program and we therefore raise our price target from $26 to $38 to reflect the higher PoS. We maintain our Neutral rating as we believe the shares are fairly priced.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.5% and a 52.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Revance Therapeutics.
Currently, the analyst consensus on Audentes Therapeutics is Moderate Buy and the average price target is $37, representing a -3.2% downside.
In a report issued on May 10, Raymond James also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42.61 and a one-year low of $13.90. Currently, Audentes Therapeutics has an average volume of 404.2K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
